Direct national medical costs specific to chronic obstructive pulmonary disease (COPD) may increase to $60.5 billion by 2029, investigators reported in Chest.
Investigators conducted a cross-sectional, retrospective study using data from the Medical Expenditure Panel Survey (MEPS) to estimate COPD-attributable direct medical costs from 2016 through 2019. National and state-specific COPD prevalence rates stratified by age were estimated with use of the 2019 American Community Survey and 2019 Behavioral Risk Factor Surveillance System data.
The researchers identified patients with COPD at least 18 years of age from 2016 to 2019 as well as a control group of individuals in the general MEPS population at least 18 years of age without COPD from 2016 to 2019.
National annual COPD-attributable medical costs from 2020 to 2029 were estimated by multiplying the projected number of patients with COPD in each age/sex category each year by the age- and sex-specific per-person COPD-attributable medical costs for that year.
“
[T]he nationwide direct medical costs attributable to COPD (adjusted for demographics and 19 concurrent conditions including COPD-related and non-COPD-related conditions) were $31.3 billion in the year 2019 and are projected to grow to $60.5 billion in 2029.
Patients with COPD (n=4135) vs those without (n=86,021) were older (mean age, 60 vs 48 years) and were more likely to be non-Hispanic White (71.2% vs 49.5%) and female (63.2% vs 53.0%).
The overall COPD-attributable medical expenditures were $31.3 billion in 2019 (95% CI, $30.28 billion-$32.44 billion), of which $17.1 billion (54.6%) was accounted for by female patients, compared with $14.2 billion (45.4%) by male patients and $17.4 billion (55.6%) by patients at least 65 years of age. Florida had the highest economic burden of COPD ($3.1 billion), with the lowest burdens seen in the District of Columbia ($41.6 million) and Alaska ($44.8 million).
The national average per-patient COPD-attributable medical costs in 2019 were $1795 (95% CI, $1734-$1858), with the highest per-patient costs in South Dakota and the lowest costs in Utah.
Among insured adults with COPD, the total national COPD-attributable medical costs by payer type in 2019 were: private insurance, $11.4 billion (95% CI, $10.95 billion-$11.89 billion) (with and without Medicare Advantage); Medicare, $10.8 billion (95% CI, $10.39 million-$11.27 billion); and Medicaid, $3.0 billion ($2.92 billion-$3.13 billion).
Based on a 5.1% annual national health expenditure per capita growth rate and annual population growth estimates, the mean COPD-attributable costs were $33.5 billion (95% CI, $32.26 billion-$34.69 billion) in 2020 and will increase to $60.5 billion ($58.07 billion-$62.67 billion) in 2029.
The estimated national average per-patient COPD-attributable medical costs in 2020 were $1895 (95% CI, $1824-$1962) and are projected to increase to $3083 (95% CI, $2962-$3196) by 2029.
This study has numerous limitations. The definition of COPD-related codes in MEPS was broad compared with other studies and may have resulted in the inclusion of younger patients and those with milder disease, leading to higher overall total medical costs and lower per patient costs. Also, the investigators used data for patients aged 45 to 64 years in each region to impute values for those aged 65 to 79 and 80+ years.
“[T]he nationwide direct medical costs attributable to COPD (adjusted for demographics and 19 concurrent conditions including COPD-related and non-COPD-related conditions) were $31.3 billion in the year 2019 and are projected to grow to $60.5 billion in 2029,” the study authors conclude. This estimate underscores “the complexity of care required by COPD patients, their unmet needs, and gaps in care” that must be taken into account in “future actions to alleviate this disease burden,” the investigators added.
Disclosure: AstraZeneca Pharmaceuticals, LP, provided funding for the research. Some of the study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.

















